The World Health Organization published guidance recommending that GLP‑1 receptor agonist medications for obesity be used alongside intensive behavioral therapy and as part of a broader obesity care ecosystem. The recommendations—summarized in JAMA and public WHO materials—advise long‑term treatment and integration of counseling to maximize and sustain clinical benefit. WHO authors also warned that global drug supply and affordability will limit immediate access: modeling cited by WHO estimates only a fraction of those who could benefit will obtain GLP‑1s in the near term. The guidance aims to steer health systems toward combined pharmacologic and nonpharmacologic care pathways rather than drug‑only interventions. Payers, health systems and manufacturers will weigh the recommendations as they design coverage policies and scale access programs worldwide.